Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;7(1):e000741.
doi: 10.1136/bmjresp-2020-000741.

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD

Felix Herth  1 , Jens M Hohlfeld  2   3 , Johannes Haas  4 , Alberto de la Hoz  5 , Xidong Jin  6 , Karl-Friedrich Kreitner  7 , Claus Vogelmeier  8 , Jens Vogel-Claussen  9 , Henrik Watz  10
Affiliations
Review

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD

Felix Herth et al. BMJ Open Respir Res. 2020 Dec.

Abstract

This exploratory, randomised, double-blind, double-dummy, multicentre, cross-over study explored the effect of 6 weeks of treatment with tiotropium/olodaterol (T/O) versus fluticasone propionate/salmeterol (F/S) on left ventricular filling in patients with chronic obstructive pulmonary disease with functional residual capacity (FRC) >120% predicted and postbronchodilator improvement of FRC ≥7.5%. Overall, 76 patients were randomised across nine sites. Treatment with T/O or F/S increased left ventricular end-diastolic volume index from baseline (adjusted mean change: T/O: 2.317 mL/m2, F/S: 2.855 mL/m2), with no statistically significant difference between treatments. However, T/O resulted in a significantly greater reduction in lung hyperinflation versus F/S (FRC plethysmography absolute change from baseline: F/S: -0.329 L, T/O: -0.581 L).

Keywords: COPD pharmacology; inhaler devices; respiratory measurement.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and patient consent: All studies included in this analysis were performed in accordance with the provisions of the Declaration of Helsinki (1996 version), the International Conference on Harmonisation Tripartite Guideline for Good Clinical Practice, applicable regulatory requirements and Boehringer Ingelheim Standard Operating Procedures. All patients provided written informed consent. This article does not report individual patient data; all data presented here are anonymised. The clinical trial protocols and the informed consent and patient information forms were reviewed and received approval/favourable opinion from a constituted local Institutional Review Board or an Independent Ethics Committee at each centre prior to the start of the study. This study was approved by Ethikkomission Medizinische Heidelberg under ID number AFmu-559/2016.

Figures

Figure 1
Figure 1
Effect of (A) T/O versus F/S on LVEDVI at week 6 and (B) T/O versus F/S on FRC plethysmograph (percent predicted and absolute change) at week 6. *P<0.01. F/S, fluticasone propionate/salmeterol; FRC, functional residual capacity; LVEDVI, left ventricular end-diastolic volume index; T/O, tiotropium/olodaterol.
See this image and copyright information in PMC

References

    1. Feary JR, Rodrigues LC, Smith CJ, et al. . Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956–62. 10.1136/thx.2009.128082 - DOI - PubMed
    1. Fuhrman C, Jougla E, Nicolau J, et al. . Deaths from chronic obstructive pulmonary disease in France, 1979-2002: a multiple cause analysis. Thorax 2006;61:930–4. 10.1136/thx.2006.061267 - DOI - PMC - PubMed
    1. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018;27:180057. 10.1183/16000617.0057-2018 - DOI - PMC - PubMed
    1. Watz H, Waschki B, Boehme C, et al. . Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008;177:743–51. 10.1164/rccm.200707-1011OC - DOI - PubMed
    1. Watz H, Waschki B, Meyer T, et al. . Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010;138:32–8. 10.1378/chest.09-2810 - DOI - PubMed

Publication types

MeSH terms